A fourth-quarter 2016 dip in income hit the 2016 financial results of Germany’s Bayer (BAYN: DE), which have shown just how crucial the strong performance of pharma is to the group's revenue and profit, in particular its anticoagulant Xarelto (rivaroxaban).
Bayer dubbed it another record year for the company and one which was successful strategically and operationally – referring in particular to the $66 billion acquisition of the USA’s GMO giant Monsanto (NYSE: MON) – but markets were not initially convinced by the results as shares dropped by 2.5 % to 106.30 euros ($111.58) by Wednesday lunchtime.
Annual sales across the group increased by 1.5% to 46.77 billion euros ($49.15 billion) compared to 2015, with pharmaceuticals accounting for 16.42 billion euros of this, a rise of 7.3%.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze